Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3.52% is 75% above its 5-year average of -13.93%, near the high end of its 5-year range (-43.62%–3.47%).
220.65% below its 12-month average of -1.10%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2.43%.
EBITDA MARGIN
-3.52%
EBITDA MARGIN AVG TTM
-1.10%
EBITDA MARGIN AVG 3Y
-4.69%
EBITDA MARGIN AVG 5Y
-13.93%
EBITDA MARGIN AVG 10Y
-52.73%
EBITDA MARGIN AVG 15Y
-68.63%
EBITDA MARGIN AVG 20Y
-79.92%
CURRENT VS TTM AVG
-220.65%
CURRENT VS 3Y AVG
+24.99%
CURRENT VS 5Y AVG
+74.74%
CURRENT VS 10Y AVG
+93.32%
CURRENT VS 15Y AVG
+94.87%
CURRENT VS 20Y AVG
+95.60%
Cerus Corporation
Market Cap
$472.58M
EBITDA Margin
-3.52%
TTM Avg
-1.10%
3Y Avg
-4.69%
5Y Avg
-13.93%
Market Cap
$474.97M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$478.28M
EBITDA Margin
-9.71%
TTM Avg
-10.19%
3Y Avg
-20.82%
5Y Avg
-63.11%
Market Cap
$476.17M
EBITDA Margin
-41.77%
TTM Avg
-67.13%
3Y Avg
-207.81%
5Y Avg
-270.93%
Market Cap
$462.71M
EBITDA Margin
-31.76%
TTM Avg
-31.76%
3Y Avg
-31.76%
5Y Avg
-31.76%
Market Cap
$460.20M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
Market Cap
$457.20M
EBITDA Margin
-1349.20%
TTM Avg
-1349.20%
3Y Avg
-1349.20%
5Y Avg
-1349.20%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cerus Corporation (CERS) | $472.58M | -3.52% | -1.10% | -4.69% | -13.93% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $474.97M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $478.28M | -9.71% | -10.19% | -20.82% | -63.11% |
| Arvinas, Inc. (ARVN)vs › | $476.17M | -41.77% | -67.13% | -207.81% | -270.93% |
| NRC Health (NRC)vs › | $463.35M | 21.99% | 25.40% | 28.98% | 31.97% |
| Contineum Therapeutics, Inc. (CTNM)vs › | $462.71M | -31.76% | -31.76% | -31.76% | -31.76% |
| Kamada Ltd. (KMDA)vs › | $460.98M | 22.80% | 21.92% | 17.96% | 15.83% |
| NeoGenomics, Inc. (NEO)vs › | $460.20M | 0.24% | -1.36% | -6.49% | -5.53% |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $457.20M | -1349.20% | -1349.20% | -1349.20% | -1349.20% |
| Assembly Biosciences, Inc. (ASMB)vs › | $441.36M | -16.58% | -87.69% | -357.20% | -653.36% |
Gross Margin
52.0%
EBITDA Margin
-3.5%
Operating Margin
-0.7%
Net Margin
-3.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2.43% |
| 2026-03-31 | 0.17% |
| 2025-12-31 | -0.43% |
| 2025-09-30 | 3.07% |
| 2025-06-30 | -5.87% |
| 2025-03-31 | -12.83% |
| 2024-12-31 | -2.20% |
| 2024-09-30 | -1.19% |
| 2024-06-30 | -7.44% |
| 2024-03-31 | -19.15% |
| 2023-12-31 | 3.47% |
| 2023-09-30 | -11.48% |
| 2023-06-30 | -28.31% |
| 2023-03-31 | -43.62% |
| 2022-12-31 | -21.12% |
| 2022-09-30 | -17.03% |
| 2022-06-30 | -14.81% |
| 2022-03-31 | -23.99% |
| 2021-12-31 | -15.43% |
| 2021-09-30 | -28.68% |
| 2021-06-30 | -43.27% |
| 2021-03-31 | -66.95% |
| 2020-12-31 | -47.98% |
| 2020-09-30 | -55.80% |
| 2020-06-30 | -64.30% |
| 2020-03-31 | -78.96% |
| 2019-12-31 | -75.46% |
| 2019-09-30 | -90.40% |
| 2019-06-30 | -88.18% |
| 2019-03-31 | -89.65% |
| 2018-12-31 | -91.51% |
| 2018-09-30 | -86.26% |
| 2018-06-30 | -79.09% |
| 2018-03-31 | -95.41% |
| 2017-12-31 | -66.50% |
| 2017-09-30 | -110.47% |
| 2017-06-30 | -165.55% |
| 2017-03-31 | -251.56% |
| 2016-12-31 | -148.67% |
| 2016-09-30 | -139.65% |
| 2016-06-30 | -175.67% |
| 2016-03-31 | -200.41% |
| 2015-12-31 | -154.74% |
| 2015-09-30 | -200.57% |
| 2015-06-30 | -171.38% |
| 2015-03-31 | -186.18% |
| 2014-12-31 | -131.53% |
| 2014-09-30 | -109.06% |
| 2014-06-30 | -127.35% |
| 2014-03-31 | -116.56% |
| 2013-12-31 | -84.00% |
| 2013-09-30 | -79.44% |
| 2013-06-30 | -69.53% |
| 2013-03-31 | -50.45% |
| 2012-12-31 | -33.69% |
| 2012-09-30 | -51.88% |
| 2012-06-30 | -51.47% |
| 2012-03-31 | -51.49% |
| 2011-12-31 | -32.89% |
| 2011-09-30 | -26.00% |
| 2011-06-30 | -80.35% |
| 2011-03-31 | -59.57% |
| 2010-12-31 | -69.12% |
| 2010-09-30 | -70.37% |
| 2010-06-30 | -56.71% |
| 2010-03-31 | -65.85% |
| 2009-12-31 | -83.21% |
| 2009-09-30 | -121.00% |
| 2009-06-30 | -125.92% |
| 2009-03-31 | -207.63% |
| 2008-12-31 | -191.86% |
| 2008-09-30 | -190.47% |
| 2008-06-30 | -223.52% |
| 2008-03-31 | -131.21% |
| 2007-12-31 | 304.60% |
| 2007-09-30 | -278.78% |
| 2007-06-30 | -414.36% |
| 2007-03-31 | -163.54% |
| 2006-12-31 | 16.50% |
| 2006-09-30 | -31.59% |
| 2006-06-30 | -89.16% |
| 2006-03-31 | -40.29% |
| 2005-12-31 | -57.04% |
| 2005-09-30 | -25.70% |
| 2005-06-30 | -51.95% |
| 2005-03-31 | -13.65% |
| 2004-12-31 | -141.53% |
| 2004-09-30 | -105.11% |
| 2004-06-30 | -252.89% |
| 2004-03-31 | -198.57% |
| 2003-12-31 | -232.62% |
| 2003-09-30 | -428.66% |
| 2003-06-30 | -736.40% |
| 2003-03-31 | -1205.67% |
| 2002-12-31 | -952.11% |
| 2002-09-30 | -2230.82% |
